Using Azithromycin to Help Indigenous Australian Infants with Bronchiolitis
Author Information
Author(s): Chang Anne B, Grimwood Keith, White Andrew V, Maclennan Carolyn, Sloots Theo P, Sive Alan, McCallum Gabrielle B, Mackay Ian M, Morris Peter S
Primary Institution: Menzies School of Health Research, Charles Darwin University
Hypothesis
The anti-microbial and anti-inflammatory properties of azithromycin will improve the clinical outcomes of Indigenous infants hospitalised with bronchiolitis.
Conclusion
The study aims to determine if azithromycin can reduce the morbidity of Indigenous infants hospitalised with bronchiolitis.
Supporting Evidence
- Bronchiolitis is the most common acute lower respiratory infection in infants worldwide.
- Indigenous infants have higher rates of hospitalisation and morbidity from bronchiolitis compared to non-Indigenous infants.
- Previous studies on macrolides for bronchiolitis have shown conflicting results.
Takeaway
This study is testing if a medicine called azithromycin can help Indigenous babies who are very sick with a lung infection called bronchiolitis feel better and stay in the hospital for less time.
Methodology
A dual centre, randomised, double-blind, placebo-controlled trial with Indigenous infants aged ≤ 24-months admitted with bronchiolitis.
Potential Biases
Potential biases may arise from the study's design, but randomisation and blinding are employed to mitigate these risks.
Limitations
The study only addresses infants hospitalised for bronchiolitis and may not account for variable presentations related to azithromycin's immune modulation effects.
Participant Demographics
Indigenous infants aged ≤ 24-months from two regional hospitals in Northern Australia.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website